ProShare Advisors
CLSD

ProShare Advisors’s Clearside Biomedical CLSD Stock Holding History

ProShare Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,046
Closed -$137K – 1802
2017
Q3 		$137K Buy
1,046
+58
+6% +$7.08K ﹤0.01% 1309
2017
Q2 		$135K Buy
988
+38
+4% +$4.56K ﹤0.01% 1387
2017
Q1 		$113K Sell
950
-44
-4% -$5.19K ﹤0.01% 1505
2016
Q4 		$133K Buy
+994
New +$250K ﹤0.01% 1658

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

ProShare Advisors's CLSD Position: Q4 2017 in Review

ProShare Advisors sold out of Clearside Biomedical (CLSD) in Q4 2017, closing a stake of 1,046 shares — an estimated $137K sold.

ProShare Advisors first reported a position in CLSD in Q4 2016 and held it in 4 quarters. The position peaked at $137K in Q3 2017. 54 funds tracked by Wall St. Rank hold CLSD as of Q4 2017.

  • ProShare Advisors reported no remaining Clearside Biomedical position as of Q4 2017 after selling out during the quarter.
  • ProShare Advisors sold 1,046 Clearside Biomedical shares in Q4 2017, an estimated $137K.
  • ProShare Advisors first reported a position in Clearside Biomedical in Q4 2016 and held it in 4 quarters.
  • ProShare Advisors's Clearside Biomedical position peaked at $137K in Q3 2017.
  • 54 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2017.

Based on ProShare Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.